Table 2 Sulfadoxine-pyrimethamine treatment outcomes
Results | no. of included patients | LF and corr. | Evaluable patients | ACPR n (%) | ETF n (%) | LCF n (%) | Total CF n (%) | LPF n (%) | Overall TF n (%) |
|---|---|---|---|---|---|---|---|---|---|
At D14 | |||||||||
Ipinda | 73 | 1 | 72 | 62(86.1) | 7(9.7) | 2(2.8) | 9(12.5) | 1(1.4) | 10(13.9) |
Mlimba | 75 | 3 | 72 | 63(87.5) | 3(4.3) | 4(5.7) | 7(9.1) | 2(2.9) | 9(12.9) |
Mkuranga | 93 | 7 | 86 | 71(82.6) | 3(3.5) | 2(2.3) | 5(6.9) | 10(11.6) | 15(17.4) |
Total | 241 | 11 | 230 | 196(85.2) | 13(5.7) | 8(3.5) | 21(9.1) | 13(5.7) | 34(14.9) |
At D28 | |||||||||
Ipinda | 72 | 0 | 72 | 44(61.1) | 7(9.7) | 5(6.9) | 12(16.7) | 16(22.2) | 28(38.9) |
Mlimba | 72 | 2 | 70 | 34(48.6) | 3(4.3) | 9(12.9) | 12(17.1) | 24(34.3) | 36(51.4) |
Mkuranga | 86 | 0 | 86 | 38(44.2) | 3(3.5) | 12(13.9) | 15(17.4) | 33(38.4) | 48(55.8) |
Total | 230 | 2 | 228 | 116(50.9) | 13(5.7) | 26(11.4) | 39(17.1) | 55(24.1) | 112(49.1) |
At D28 PCR-corrected | |||||||||
Ipinda | 72 | 6 | 66 | 44(66.7) | 7(9.7) | 5(6.9) | 12(16.7) | 10(13.9) | 22(33.3) |
Mlimba | 70 | 10 | 60 | 34(56.7) | 3(4.3) | 5(7.1) | 8(11.4) | 18(25.7) | 26(43.3) |
Mkuranga | 86 | 11 | 75 | 38(50.7) | 3(3.5) | 8(9.3) | 11(12.8) | 26(30.2) | 37(49.3) |
Total | 228 | 27 | 201 | 116(57.7) | 13(5.7) | 18(7.9) | 31(13.6) | 54(23.7) | 85(42.3) |